Brown Jennifer R
Director, CLL Center, Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA , USA , and Department of Medicine, Harvard Medical School , Boston, MA , USA.
Leuk Lymphoma. 2014 Feb;55(2):263-9. doi: 10.3109/10428194.2013.803226. Epub 2013 Jun 24.
Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia. This review evaluates the data from ongoing clinical and correlative studies of ibrutinib in B cell malignancies with a particular focus on CLL, and considers these data in the context of other B cell receptor pathway inhibitors.
近期临床数据表明，第一代布鲁顿酪氨酸激酶（BTK）共价抑制剂依鲁替尼在慢性淋巴细胞白血病（CLL）中具有显著活性，在其他B细胞恶性肿瘤中也具有出色活性，尤其包括套细胞淋巴瘤和华氏巨球蛋白血症。本综述评估了依鲁替尼在B细胞恶性肿瘤中正在进行的临床及相关研究的数据，特别关注CLL，并结合其他B细胞受体通路抑制剂来考量这些数据。
